论文信息 - Cirmtuzumab, an Anti-ROR1 Antibody, in Combination with Ibrutinib: Clinical Activity in Mantle Cell Lymphoma (MCL) or Chronic Lymphocytic Leukemia (CLL) from a Phase 1/2 Study - 字舞流文

Cirmtuzumab, an Anti-ROR1 Antibody, in Combination with Ibrutinib: Clinical Activity in Mantle Cell Lymphoma (MCL) or Chronic Lymphocytic Leukemia (CLL) from a Phase 1/2 Study

Michael L. Wang | T. Kipps | G. Chung | C. Jamieson | W. Wierda | J. Tuscano | T. Siddiqi | H. Lee | E. Weihe | I. Isufi | A. Goldenberg | J. Breitmeyer | F. Hsu | N. Lamanna | L. Leslie | J. Barrientos | J. Koff | S. Subbiah | M. Choi | X. Ianopulos